返回 Agenda
Session Chair(s)
Mark Rutter
Co-Founder, Head of Product Development & Strategy
RxTROSPECT, United States
Speaker(s)
Optimisation of the Regulatory Framework for Orphan Medicines to Encourage Innovative Treatments for Patients
Agnes Mathieu-Mendes, RPH
European Health & Digital Executive Agency (HaDEA), Belgium
Head of Unit
Orphan Medicinal Products and the Major Contribution to Patient Care
Jordi Llinares Garcia, MS
European Medicines Agency, Netherlands
Head of Research and Innovation
The Patient’s Perspectives on OMPs and Significant Benefit
Virginie Hivert, PHARMD, PHD
Eurordis-Rare Diseases Europe, France
Therapeutic Development Director
Evolution of the Significant Benefit Framework - An Industry Perspective
Mark Rutter
RxTROSPECT, United States
Co-Founder, Head of Product Development & Strategy